Skip to main content
. 2024 Jun 28;79:100421. doi: 10.1016/j.clinsp.2024.100421

Table 3.

Association between IBD and parenteral malignancies.

Exposures Outcomes IVW
OR (95% CI) p Power (%)
IBD FinnGen
Diffuse large B-cell lymphoma 1.2450 (1.0311‒1.5034) 0.023 100
UC FinnGen
Non-melanoma skin cancer 1.0449 (1.0030‒1.0886) 0.035 100
Melanoma 1.0280 (0.9860‒1.0718) 0.019 98
Skin cancer 0.8581 (0.6283‒1.1720) 0.336
UKB
Non-melanoma skin cancer 1.0034 (1.0015‒1.0052) <0.001 8
Melanoma 1.0003 (0.9998‒1.0008) 0.311
Skin cancer 1.0004 (1.0001‒1.0006) 0.007 9
CD FinnGen
Non-melanoma skin cancer 1.0288 (1.0023‒1.0560) 0.034 99
Melanoma 1.0004 (0.7892‒1.2680) 0.998
Skin cancer 1.0287 (1.0022‒1.0559) 0.033 99
UKB
Non-melanoma skin cancer 1.0017 (1.0001‒1.0033) 0.033 6
Melanoma 1.0004 (0.9999 ‒1.0008) 0.076
Skin cancer 1.0002 (0.9999 ‒1.0005) 0.078

IBD, Inflammatory Bowel Disease; IVW, Inverse Variance Weighted; OR, Odds Ratio, CI, Confidence Interval; UC, Ulcerative Colitis; UKB, the UK Biobank; CD, Crohn's Disease.